Literature DB >> 6258283

Induction of retinal degeneration in cats by methylnitrosourea and ketamine hydrochloride.

J P Schaller, M Wyman, S E Weisbrode, R G Olsen.   

Abstract

Persistent mydriasis seen in cats used in an oncology study apparently was not related to neoplasia. Ophthalmoscopically, the cats had severely atrophic retinas and clinically observable visual impairment. These findings were confirmed by electroretinographic and histologic examination. Cats with these retinal lesions had received combinations of methylnitrosourea, ketamine hydrochloride, and feline leukemia virus. Retinopathy was not seen in ketamine-anesthetized cats receiving feline leukemia virus. To test the nature of this phenomenon, four cats were given both drugs and three received methylnitrosourea alone. The four cats developed severe generalized retinal degeneration by day 5, whereas the three cats given methylnitrosourea alone had normal retinas. Histologic changes in the affected cats were extensive loss of rods and cones, and of the outer nuclear layer. The electroretinographic responses to white light were depressed or extinguished. Retinal degeneration, therefore, appeared to be dependent upon administration of both methylnitrosourea and ketamine hydrochloride.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6258283     DOI: 10.1177/030098588101800212

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  3 in total

1.  History and clinical signs.

Authors:  Bruce H Grahn; Eric S Storey; Cheryl L Cullen
Journal:  Can Vet J       Date:  2002-02       Impact factor: 1.008

2.  Diagnostic ophthalmology. Retinal degeneration.

Authors:  B H Grahn; J Wolfer; J Krahn
Journal:  Can Vet J       Date:  1996-03       Impact factor: 1.008

3.  Development of Animal Models for Lens and Corneal Diseases Using N-Methyl-N-Nitrosourea.

Authors:  Yingxin Qu; Runpu Li; Xiaoqi Li; Qinghua Yang; Jianwen Chen; Yan Dong; Wentian Xiao; Shuo Zheng; Liqiang Wang; Ye Tao; Yifei Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-07-01       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.